Key clinical point: In patients with migraine, treatment with anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) reduced visual hypersensitivity, and this reduction was positively associated with a decrease in monthly migraine days (MMD).
Major finding: After 3 months of treatment with anti-CGRP mAb, the mean ictal Leiden Visual Sensitivity Scale (L-VISS) score decreased from 20.1 to 19.2 ( P = .042) and the mean interictal L-VISS score decreased from 11.8 to 11.1 ( P = .050), and a positive correlation was observed between the reduction in MMD and the decrease in ictal L-VISS (β 0.3; P = .001) and interictal L-VISS (β 0.2; P = .010) scores.
Study details: This prospective follow-up study included 205 patients with migraine who were treated with either erenumab (n = 105) or fremanezumab (n = 100).
Disclosures: This study did not disclose the funding source. Three authors declared receiving consultancy or industry and independent support from various sources. The other authors declared no conflicts of interest.
Source: de Vries Lentsch S et al. Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies. Headache. 2023;63(7):926-933 (Jun 26). Doi: 10.1111/head.14531